bioRxiv Science⌕ Search

Biology subjects

Powsner, E.

Publications and source records attributed to Powsner, E..

2 recordsLinked to original sources

Perfusion Bioreactor Culture Incorporating Mechanical Confinement Enhances Mesenchymal Stem Cell Extracellular Vesicle Production and Wound Healing Potential

Mesenchymal stem cell extracellular vesicles (MSC EVs) have been widely studied for regenerative medicine and tissue repair applications. However, clinical translation of EV therapeutics has been hampered by low potency and lack of scalable production strategies. This work aims to develop a novel approach that exploits the mechanosensitivity of MSCs to enhance EV potency in the context of enhanced production via bioreactor culture. MSCs are well known to respond to mechanical stimuli such as substrate stiffness and shear stress, and here it is shown that exposing MSCs to another mechanoregulatory parameter, confinement, enhances the pro-angiogenic bioactivity of their EVs. This is consistent across both donor-derived primary MSCs and induced pluripotent stem cell-derived MSCs (iMSCs). The development of a 3D-printed perfusion bioreactor system that enables culture of confined MSCs under flow is also detailed here, resulting in a 67-fold increase in EV production compared to flask culture. iMSC EVs obtained downstream of this confinement-bioreactor culture induce greater vascularization and generally improve wound healing in a diabetic mouse model compared to iMSC EVs from conventional tissue culture. Overall, this work establishes the development of a scalable, bioreactor-based iMSC EV production platform that provides a solution to major translational bottlenecks of therapeutic EVs.

bioengineering↗

Induced pluripotent stem cell-derived extracellular vesicles promote wound repair in a diabetic mouse model via an anti-inflammatory immunomodulatory mechanism

Extracellular vesicles (EVs) derived from mesenchymal stem/stromal cells (MSCs) have recently been widely explored in clinical trials for treatment of diseases with complex pathophysiology. However, production of MSC EVs is currently hampered by donor-specific characteristics and limited ex vivo expansion capabilities before decreased potency, thus restricting their potential as a scalable and reproducible therapeutic. Induced pluripotent stem cells (iPSCs) represent a self-renewing source for obtaining differentiated iPSC-derived MSCs (iMSCs), circumventing both scalability and donor variability concerns for therapeutic EV production. Thus, we initially sought to evaluate the therapeutic potential of iMSC EVs. Interestingly, while utilizing undifferentiated iPSC EVs as a control, we found that their vascularization bioactivity was similar and their anti-inflammatory bioactivity was superior to donor-matched iMSC EVs in cell-based assays. To supplement this initial in vitro bioactivity screen, we employed a diabetic wound healing mouse model where both the pro-vascularization and anti-inflammatory activity of these EVs would be beneficial. In this in vivo model, iPSC EVs more effectively mediated inflammation resolution within the wound bed. Combined with the lack of additional differentiation steps required for iMSC generation, these results support the use of undifferentiated iPSCs as a source for therapeutic EV production with respect to both scalability and efficacy.

bioengineering↗